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ABSTRACT
Background The main symptom of postoperative ileus
(POI) is an intestinal motility disorder in which
monocytes/macrophages and neutrophils play crucial
roles. Prokinetic 5-hydroxytryptamine 4 receptor
(5-HT4R) agonists and dopamine receptor
antagonists are potential therapeutic agents for
directly ameliorating the motility disorder associated with
POI.
Aim To determine the effects of the 5-HT4R agonists
mosapride citrate (MOS) and CJ-033466 on intestinal
smooth muscle contractility relative to immune reactions
after POI.
Methods Intestinal manipulation (IM) was applied to the
rat distal ileum. Both MOS (0.3 and 1 mg/kg, s.c.) and
CJ-033466 (1 mg/kg, s.c.) were administered to the
animals before and after IM. At 24 h after IM,
isolated intestinal smooth muscle contractile activity in
vitro, gastrointestinal transit in vivo, inﬂammatory
mediator expression and leucocyte inﬁltration were
measured.
Results After IM, ileal circular muscle contractility in
vitro and gastrointestinal transit in vivo were reduced
and the number of macrophages and neutrophils
increased in the inﬂamed muscle layer, resulting in the
induction of inﬂammatory mediators such as interleukin
1 b (IL-1b), IL-6, tumour necrosis factor a (TNFa),
monocyte chemoattractant protein 1 (MCP-1) and
inducible nitric oxide synthase (iNOS). Both MOS and
CJ-033466 signiﬁcantly attenuated not only the
intestinal motility dysfunction but also the leucocyte
inﬁltration and inﬂammatory mediator expression after
IM. The autonomic ganglionic blocker hexamethonium
(1 mg/kg, i.p.) and the a7-nicotinic acetylcholine
receptor (a7nAChR) antagonist methyl
lycaconitine citrate (0.087 mg/kg, i.p.) blocked
MOS-mediated ameliorative actions.
Immunohistochemically, a7nAChR is expressed by
monocytes/macrophages but not by neutrophils in the
inﬂamed intestine.
Conclusion Stimulating the 5-HT4R accelerates acetyl
choline (ACh) release from cholinergic myenteric
neurons, which subsequently activates a7nAChR on
activated monocytes/macrophages to inhibit their
inﬂammatory reactions in the muscle layer. In addition to
their gastroprokinetic action, 5-HT4R agonists might
serve as novel therapeutic agents for POI characterised
by anti-inﬂammatory potency.
INTRODUCTION
Various 5-HT4R agonists, such as tegaserod,
cisapride and mosapride, have been clinically vali-
dated as treatment for gastrointestinal disorders
characterised by dysmotility. Originally, 5-HT4R
agonists were believed to induce prokinetic potency
< Additional ﬁgures are
published online only. To view
these ﬁles please visit the
journal online (http://gut.bmj.
com).
1Department of Veterinary
Pharmacology, Graduate School
of Agriculture and Life Sciences,
The University of Tokyo, Tokyo,
Japan
2Department of Metabolic Care
and Gastrointestinal Surgery
Graduate School of Medicine,
The University of Tokyo, Tokyo,
Japan
3Department of Veterinary
Science, Nippon Veterinary and
Life Science University, Tokyo,
Japan
Correspondence to
Dr Masatoshi Hori, Department
of Veterinary Pharmacology, The
University of Tokyo, 1-1-1 Yayoi,
Bunkyo-ku, Tokyo 113-8657,
Japan;
ahori@mail.ecc.u-tokyo.ac.jp
Revised 21 October 2010
Accepted 25 October 2010
Published Online First
29 November 2010
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
gut.bmj.com/site/about/
unlocked.xhtml
Signiﬁcance of this study
What is already known about this subject?
< The 5-HT4R agonist mosapride is actually used
in clinical practice as a gastrointestinal proki-
netic drug.
< Recent clinical trials showed that mosapride,
that is benzamide analogues of cisapride, reduce
postoperative ileus although pharmacological
mechanisms are not well understood.
< Stimulation of the vagus nerve prevents post-
operative ileus through a7nAChR in macro-
phages.
What are the new ﬁndings?
< The 5-HT4R agonist mosapride dramatically
inhibits postoperative ileus through anti-inﬂam-
matory reaction in addition to its gastrointestinal
prokinetic action.
< The anti-inﬂammatory action is mediated by
acetylcholine (ACh) release from cholinergic
myenteric neurons, which subsequently acti-
vates a7nAChR on activated monocytes/macro-
phages to inhibit inﬂammation.
< For the ﬁrst time, we found a new subset of
activated macrophages expressed a7nAChR
during inﬂammation in small intestine.
How might it impact on clinical practice in the
foreseeable future?
< 5-HT4R agonists, such as mosapride, could be
clinically used not only as a gastrointestinal
prokinetic drug but also as anti-inﬂammatory
drug to prevent postoperative ileus.
< Intestinal macrophages are unique immunoreac-
tive cells inducing a7nAChR during inﬂamma-
tion, which give a signiﬁcant impact on medical
sciences.
< 5-HT4R could be a new therapeutic molecular
target for anti-inﬂammatory gastrointestinal
diseases.
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Neurogastroenterologyonly in the upper part of the gastrointestinal tract. Therefore,
5-HT4R agonists are still clinically used to treat gastroparesis
and functional dyspepsia.
1e3 However, 5-HT4R agonists can also
induce prokinetic ability in the lower part of the gastrointestinal
tract in experimental animals and humans,
45and they are
clinically applied to treat chronic constipation and constipation-
predominant irritable bowel syndrome.
67Indeed, immunohis-
tochemical studies have identiﬁed 5-HT4R in the myenteric and
submucosal ganglia of gastrointestinal tissues.
8e10
Postoperative ileus (POI) is a common complication after
intra-abdominal surgery that is accompanied by increased
morbidity and prolonged hospitalisation, increasing hospital
costs.
11 Neurogenic, inﬂammatory and inﬂammatoryeneuronal
interactive mechanisms are generally considered to induce
POI.
12 Sympathetic reﬂexes, the activation of non-adrenergic,
non-cholinergic nerves, inhibitory humoural agents and the
inﬂuence of anaesthetics play crucial roles in the pathogenesis of
POI at the acute stage during and shortly after (up to 3 h)
laparotomy and abdominal surgery.
13 14 Local inﬂammatory
responses in the manipulated intestine additionally participate
in disordered motility during the later stage of POI (24 h after
surgery).
15e19 Many resident macrophages are distributed in the
subserosal, myenteric plexus regions of the intestinal muscle
layer and inside the circular smooth muscle layer under healthy
conditions.
20 21 Although these ramiﬁed forms of resident
macrophages normally remain inactive,
22 23 inﬂammatory
stimuli and/or mechanical stress induced by IM activates them
to produce prostaglandins, nitric oxides, inﬂammatory cytokines
and chemokines that cause muscularis inﬂammation and
intestinal motility disorders.
15e19 24
The pharmacological management of POI is important to
inhibit morbidity rates and reduce hospital costs and length of
hospital stay. Gastrointestinal prokinetic agents might be useful
for managing or preventing POI according to some clinical
trials.
25e28 The effects of various gastrointestinal prokinetic
agents on postoperative ileus have also been investigated in
experimental animals.
29 Peripherally acting m-opioid receptor
antagonists, such as alvimopan and methylnaltrexone, offer
promising results for preventing prolonged POI
28 and 5-HT4R
agonists that are benzamide analogues of cisapride and MOS also
reduce POI, whereas the partial 5-HT4R agonistic and dopamine
D2 antagonistic agent metoclopramide does not have preventive
action.
28 30 These results suggest that the ameliorative actions of
cisapride and MOS are not simply mediated by gastrointestinal
prokinetic actions through 5-HT4R, and that other mechanisms
are involved. In the present study, therefore, we investigated how
5-HT4R agonists prevent POI in a rat model.
MATERIALS AND METHODS
Animal model of POI
Male SpragueeDawley rats (250e400 g; Charles River Japan,
Yokohama, Japan) were manipulated and cared for in strict
compliance with the Guide to Animal Use and Care published by
the University of Tokyo. The Institutional Review Board of the
Graduate School of Agriculture and Life Sciences of the
University of Tokyo approved the study protocol.
All animals were anaesthetised with pentobarbital sodium
(ScheringePlough Corp., Kenilworth, New Jersey, USA) and the
animal model of POI was made by intestinal manipulation (IM)
previously reported.
15e19
Experimental design
The rats were randomly assigned to the following groups:
Control, no treatment with fasting; IM + Vehicle, sterilised
physiological saline was subcutaneously injected at 2 h before
and at 2 and 6 h after IM; IM + MOS and IM+CJ, 5-HT4R
agonist MOS citrate (0.3, 1 mg/kg, donated by Dainippon
Sumitomo Pharma) or CJ-033466 (CJ; 1 mg/kg, donated by
Pﬁzer) were similarly administered three times, respectively; IM
+ MOS + GR, the 5-HT4R antagonist GR113808 (GR; 1 or
3 mg/kg, Sigma Aldrich, St. Louis, Missouri, USA) was similarly
administered by three intraperitoneal (i.p.) injections with
MOS; IM + MOS + HEX, the non-speciﬁc autonomic gangli-
onic blocker hexamethonium chloride (1 mg/kg; Nacalai Tesque,
Kyoto, Japan) was applied at 1 h before IM and MOS was
applied at 2 h before and at 2 and 6 h after IM; IM + MOS +
MLA, the a7-nicotinic acetylcholine receptor (a7nAChR)
antagonist methyl lycaconitine (MLA) citrate (0.087 mg/kg;
TOCRIS, Bristol, UK) was injected i.p. at 30 min before each
MOS application. Both MOS and GR113808 were dissolved in
1% of lactic acid with physiological saline and other substances
were dissolved in distilled water.
Contraction studies
The manipulated ileal portion was isolated from POI model rats
at 24 h after IM. The ileum was cut open along the mesenteric
attachment, and the mucosal and submucosal layers were gently
removed. Circular strips were suspended along the circular axis
in a tissue bath ﬁlled with a normal physiological salt solution
comprising (in mM) 136.9 NaCl, 5.4 KCl, 1 CaCl2, 1.5 MgCl2,
23.8 NaHCO3, 5.5 glucose, and 0.01 EDTA (pH 7.4). Muscle
strips were maintained at 378C and aerated with 95% O2e5%
CO2. Responses of the strips were measured isometrically under
a resting tension of 10 mN. The magnitude of absolute force was
normalised to the wet weight of each strip.
Intestinal transit determination
After 18 h of fasting, the rats were randomly assigned to four
groups (Control, IM + Vehicle, IM + MOS (MOS 1 mg/kg), IM
+ MOS + MLA (MOS 1 mg/kg, MLA 0.087 mg/kg) to measure
gastrointestinal transit. Twenty-two hours after IM, 200 mlo f
the non-absorbable marker 0.25% (w/v) phenol red in 5% (w/v)
glucose was orally administered to the rats via a gastric tube.
After 1 h later, the gastrointestinal part was isolated and
stomach and intestine were separated as a single segment (Sto)
and divided into ten segments (Sl1eSl10), respectively. The
measurement of volume of each segment and calculation of the
geometric center of distribution of phenol red were performed as
previously reported.
17 18
Whole mount immunohistochemistry
Whole mount muscularis preparations were basically performed
in an orderly manner previously reported.
23 24 Each ﬁrst and
second antibody are listed in table 1. Preparations were
Table 1 Antibodies used for immunohistochemistry
Antibody Dilution
Anti-ED1mouse monoAb (BMA) 1:500
Alexa Fluor 488 conjugated anti-mouse IgG donkey polyAb (Invitrogen) 1:500
Alexa Fluor 568 conjugated anti-mouse IgG donkey polyAb (Invitrogen) 1:500
Anti-ED2 mouse monoAb (BMA) 1:500
Alexa Fluor 488 conjugated anti-mouse IgG donkey polyAb (Invitrogen) 1:500
Anti-PGP9.5 rabbit polyAb (UltraClone) 1:3000
Alexa Fluor 568 conjugated anti-rabbit IgG goat polyAb (Invitrogen) 1:500
Anti-a7nAChR(C-20) goat polyAb (Santa Cruz Biotechnology) 1:200
Alexa Fluor 488 conjugated anti-goat IgG rabbit polyAb (Invitrogen) 1:500
FITC-conjugated a-bungarotoxin (Biotium, Hayward) 5 mg/ml
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Neurogastroenterologyimmunohistochemically analysed using an LSM510 confocal
microscope (Carl Zeiss Japan, Tokyo, Japan) and a Digital Eclipse
C1 (Nikon, Tokyo, Japan). Immunopositive cells in the myen-
teric plexus and the subserosal layers of three randomly selected
areas in each preparation were counted and then the averaged
value was calculated. The same experiment was performed at
least four times to calculate means 6 SE.M.
Myeloperoxidase staining
Whole mount preparations of ileal muscularis region were cut
into 0.531 cm pieces and ﬁxed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 30 min at 48C. The prepa-
rations were washed with Tris-buffered saline (TBS) for 1 h,
incubated in physiological salt solution containing 0.1% (w/v)
HankereYates reagent (Polysciences, Warrington, Pennsylvania,
USA) and 0.03% (v/v) hydrogen peroxidase (Mitsubishi Gas
Chemical Company, Tokyo, Japan) for 10 min and then rinsed
Table 2 Sequences of PCR primers and their Tm values and product
sizes
Gene Sequences (S: sense, As: antisense) Tm (8C)
Product
size (bp)
GAPDH S: 59-TCCCTCAAGATTGTCAGCAA-39
As: 59-AGATCCACAACGGATACA TT-39
58 308
IL-1b S: 59-TCCATGAGCTTTGTACAAGG-39
As: 59-GGTGCTGATGACCAGTTGG-39
52 246
IL-6 S: 59-CAAGAGACT TCCAGCCAGTTGC-39
As: 59-TTGCCGAGTAGACCTCATAGTGAC-39
48 614
TNFa S: 59-AAATGGGCTCCCTCTCATCA-39
As: 59-AGCCTTGTCCCTTGAAGAGA-39
52 248
MCP-1 S: 59-CAACTCTCACTGAAGCCAGA-39
As: 59- AAATGGATCTACATCTTGCA-39
54.5 600
iNOS S: 59-AAGGGAGTGTTGTTCCAGGT-39
As: 59-CCACCAGCTTCTTCAAAGTG -39
52 196
5-HT4RS : 5 9-CTTCGGTGCCATTGAGTTG-39
As: 59-GCATAGGGCTTGTTGACCAT-39
58 354
a7-nAChR S: 59-ATGGTGGCAAATGCCTAAG-39
As: 59-CTCGGAAGCCAATGTAGAGC-39
58 204
Figure 1 Effects of 5-HT4R agonists on motility dysfunction and leucocyte inﬁltration induced by intestinal manipulation (IM). (A) Effects of IM on
carbachol-induced contractions in intestinal circular smooth muscles and effect of mosapride citrate (MOS) and CJ-033466 (CJ) on contractility.
**Signiﬁcantly different from IM (n¼4 each). (B) Typical results of whole mount immunohistochemical staining of myenteric plexus region to detect
ED2-positive resident macrophages, ED1-positive monocyte-derived macrophages and MPO-positive neutrophils. Red signals indicate PGP9.5-positive
myenteric nerves. Green signals indicate ED2- or ED1-positive macrophages. (CeE) Quantiﬁcation of leucocytes in subserosal and myenteric plexus
regions; # and ##, signiﬁcantly different from control at p<0.05 or p<0.01, respectively; * and **, signiﬁcantly different from number of leucocytes
in IM intestine at p<0.05, and p<0.01, respectively. MOS (0.3 or 1 mg/ml, s.c.) and CJ-033466 (1 mg/kg, s.c.) were administered as described in
Materials and methods. Bars show means 6 SEM from four independent experiments.
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Neurogastroenterologyin PBS for 10 min. Cells that were obviously myeloperoxidase
(MPO)-positive (neutrophils) in the muscularis and subserosal
layers were counted under a microscope (Nikon ACT-1C for
DXM1200; Nikon, Tokyo, Japan) in ﬁve randomly selected areas
of each preparation. Some preparations were also analysed
immunohistochemically using ED1 or ED2 after MPO staining.
Quantitative RT-PCR
Quantitative RT-PCR proceeded as described.
24 The sequences of
the primer and expected product size are listed in table 2.
Ampliﬁcation proceeded in a PCR Thermal Cycler MP (TaKaRa
Biomedicals, Shiga, Japan) using 30e34 cycles (two-cycle inter-
vals), each consisting of 988C for 10 s, 52e588C for 30 s, and
728C for 1 min. The products of each cycle were resolved on 2%
agarose gels containing 0.1% ethidium bromide, and the optimal
number of PCR cycles for quantiﬁcation was selected. The
density of detectable ﬂuorescent bands was measured using NIH
Image software (Image J, Ver. 1.38x).
Statistics
Results are expressed as means 6 SEM. Data were statistically
evaluated using unpaired Student t tests for comparisons
between two groups and by one-way analysis of variance
(ANOVA) followed by Dunnett’s test for comparisons among
three or more groups. Values of p<0.05 were considered statis-
tically signiﬁcant.
RESULTS
5-HT4R stimulation ameliorates motility dysfunction induced by
intestinal manipulation in a post-operative ileus model rat
intestine
Carbachol (CCh) concentration-dependently induced and
signiﬁcantly diminished contractions in ileal circular smooth
muscle tissues isolated from the small intestines of normal and
POI model rats, respectively. The nitric oxide synthase inhibitor,
N
G-nitro-L-arginine methyl ester (L-NAME, 300 mM; n¼4; IM
(CCh 1 mM), 0.045560.0090 mN/mg; IM+L-NAME (CCh; mM),
0.271460.0662 mN/mg; p<0.01) almost completely recovered
the decreased contractility, suggesting that the motility
dysfunction induced by IM is mediated by NO generated from
inducible nitric oxide synthase. Figure 1A shows that
the decreased intestinal motility was almost completely recov-
ered in the ileal tissue isolated from POI model rats treated with
1 mg/kg s.c. of either of the speciﬁc 5-HT4R agonists MOS or
CJ-033466.
5-HT4 receptor stimulation inhibited inﬂammation induced by
intestinal manipulation
We immunohistochemically monitored changes in ED2-
positive resident macrophages, ED1-positive monocyte-derived
macrophages, and MPO-stained neutrophils (ﬁgure 1BeE). Many
ED2-positive resident macrophages were detected in the myen-
teric plexus and subserosal regions of the control rat ileal muscle
layer (ﬁgure 1B, C). On the other hand, ED1-positive monocyte-
derived inﬁltrating macrophages and MPO-positive inﬁltrating
neutrophils were undetectable in control animals (ﬁgure 1B, D).
The ED2-positive resident macrophage population was increased
by 25% in the inﬂamed muscle layer of the intestine of the POI
model rat compared with that of control rats. On the other hand,
many ED1-positive monocyte-derived macrophages and MPO-
stained neutrophils inﬁltrated into the myenteric plexus region
and subserosal region 24 h after the intestinal inﬂammation.
Interestingly, monocyte-derived macrophages and neutrophil
populations were signiﬁcantly inhibited in both regions of ileal
tissues isolated from the POI model rat intestine treated with
MOS and CJ-033466 (ﬁgure 1D, E). The increased number of
ED2-positive muscularis resident macrophages after IM was
not changed by 5-HT4R stimulation with MOS and CJ-033466
(ﬁgure 1C). Neither MOS nor CJ-033466 at 1 mg/kg, s.c. affected
themacrophageandneutrophilpopulationsinthemusclelayerof
control rats (n¼4 each; data not shown).
We further investigated the effects of GR113808, a 5HT4
receptor selective antagonist, on the MOS-induced anti-inﬂam-
matory reactions and its ameliorative effect on intestinal
motility dysfunction (ﬁgure 2). GR113808 (1, 3, 10 mg/kg, i.p.)
Figure 2 Effect of the 5-HT4R antagonist GR113808 on MOS-induced
leucocyte inﬁltration and motility dysfunction. Numbers of ED1-positive
monocyte-derived macrophages (A) and MPO-stained neutrophils (B) in
myenteric plexus region; ##, signiﬁcantly different from control at
p<0.01; **, signiﬁcantly different from IM at p<0.01; jj, signiﬁcantly
different from IM with MOS (IM+MOS). Each bar shows mean6SEM
from three independent experiments. (C) Changes in intestinal muscle
contraction induced by CCh. MOS (1 mg/kg) and GR113808 (1, 3 and
10 mg/kg) were administered as described in Materials and methods. *
and **, signiﬁcantly different from IM+MOS (n¼4 each). CCh,
carbachol chloride; IM, intestinal manipulation; MOS, mosapride citrate;
MPO, myeloperoxidase.
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Neurogastroenterologyabolished the inhibitory effect of MOS on the inﬁltration of
monocyte-derived macrophages and neutrophils into the
inﬂamed muscle layer (ﬁgure 2A, B). In addition, GR113808
suppressed the ameliorative effect of MOS on the IM-mediated
motility dysfunction (ﬁgure 2C). GR113808 (1 mg/kg, i.p.) did
not affect the populations of ED1-positive macrophages and
neutrophils in the muscle layer of control rat intestine (n¼4,
data not shown).
To evaluate the inﬂammation in the muscle layer of ileum
after IM, we investigated changes in interleukin-1 b (IL-1b), IL-6,
tumour necrosis factor a (TNF-a), monocyte chemoattractant
protein-1 (MCP-1) and inducible nitric oxide synthase (iNOS)
levels at 6 h after IM by quantitative RT-PCR. The mRNA
expression of IL-1b, MCP-1 and iNOS was signiﬁcantly elevated
by IM, which was remarkably attenuated by MOS. The mRNA
expression of TNFa and IL-6 tended to increase and MOS also
inhibited the tendency (ﬁgure 3).
Anti-inﬂammatory reaction induced by 5-HT4R stimulation is
caused by a neurogenic reaction
Stimulating the 5-HT4R activates myenteric plexus cholinergic
neurons to release acetyl choline (ACh), which in turn induces
gastroprokinetic action in the gastro intestine.
4 5 Therefore,
we used the autonomic ganglionic blocker HEX to investigate
whether the MOS-mediated anti-inﬂammatory actions
are neurogenically mediated (ﬁgures 4 and 5). HEX (1 mg/kg,
i.p.) did not affect the populations of ED1-positive macrophages
and MPO-positive neutrophils in the myenteric plexus or in
the subserosal region of the control rat intestine (n¼4; values are
cells/mm
2; ED1: myenteric, 6.7666.43; subserosa, 5.4661.22;
MPO: myenteric 23.3266.98; subserosa, 5.3961.42). HEX
also did not affect the increase in inﬁltration by ED1-positive
macrophages and neutrophils induced by IM (n¼4; values
are cells/mm
2; ED1: myenteric, 1245.926186.57; subserosa,
1150.936115.43; MPO: myenteric, 911.05660.49; subserosa,
1011.19683.68). However, HEX signiﬁcantly reduced the ability
of MOS to inhibit inﬁltration by ED1-positive macrophages and
MPO-stained neutrophils (ﬁgures 4 and 5A,B).
We then investigated the effect of HEX on the MOS-induced
amelioration of motility dysfunction by IM (ﬁgure 5C).
HEX (1 mg/kg, i.p.) did not affect the CCh (1 mm)-induced
contractility of ileal tissue isolated from normal and POI model
rats (n¼4 each; values are mN/mg; normal rat, 0.281560.0648;
normal rat with HEX, 0.236360.0575; POI model
rat, 0.044060.0090; POI model rat with HEX, 0.075060.0156).
However, HEX abolished the ability of MOS to improve the
motility dysfunction in the POI model rat intestine.
Figure 3 Effects of 5-HT4R activation
on expression of inﬂammatory
mediators in inﬂamed muscle layer of
a post-operative ileus (POI) model rat
small intestine. Detailed procedures and
predicted sizes of PCR products are
described in Materials and methods.
##, signiﬁcantly different from control
at p<0.01; ##, signiﬁcantly different
from control at p<0.01; **, signiﬁcantly
different from intestinal manipulation
(IM). Each bar shows mean 6 SEM
from four independent experiments.
Figure 4 Effects of the autonomic
ganglionic blocker hexamethonium and
a7nAChR antagonist methyl
lycaconitine (MLA) on inﬁltration of ED1-
positive monocyte-derived macrophages
and myeloperoxidase (MPO)-stained
neutrophils into subserosal region after
intestinal manipulation (IM). Data are
typical ﬁndings from four independent
experiments. Mosapride (MOS; 1 mg/
kg, s.c.), hexamethonium (1 mg/kg, i.p.)
and MLA (0.087 mg/kg, i.p.) were
administered as described in Materials
and methods.
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NeurogastroenterologyMethyl lycaconitine citrate, an a7nAChR antagonist, abolished
the anti-inﬂammatory action induced by 5-HT4R stimulation
Cholinergic neuronal stimulation induces immuno-suppressive
actions through a7nAChR on immunoreactive cells such as
macrophages and Tcells,
31 suggesting that 5-HT4R stimulation
activates cholinergic neurons to release ACh, which may
secondarily result in a7nAChR activation in immunoreactive
cells. We therefore investigated the effect of the a7nAChR
antagonist methyl lycaconitine citrate (MLA) on MOS-induced
anti-inﬂammatory reactions in the POI model rat intestine.
We conﬁrmed that MLA (0.087 mg/kg, i.p.) did not affect
inﬁltration by ED1-positive macrophages and MPO-stained
neutrophilsincontrolandPOImodelratintestines(n¼4;datanot
shown).However,MLAcompletelysuppressedtheMOS-induced
anti-inﬂammatory activity determined as macrophage and
neutrophil inﬁltration into the muscle layer (ﬁgures 4 and 5A, B).
We also examined effect of MLA on the MOS-induced
ameliorative effect on IM-mediated motility dysfunction
(ﬁgure 5C). MLA (0.087 mg/kg i.p.) did not affect the CCh
(1 mM)-induced contraction of ileal tissue in control and POI
model rats (n¼4 each; values are mN/mg; normal rat,
0.281560.0648; normal rat with MLA, 0.251260.0291; post-
operative ileus model rat, 0.044060.0090; postoperative ileus
model rat with MLA, 0.056560.0101). Figure 5C shows that
MLA (0.087 mg/kg i.p.) inhibited the ameliorative action of
MOS on intestinal dysmotility caused by IM.
To conﬁrm the effect of MLA on MOS-induced ameliorative
action for IM-mediated gastrointestinal motility disorder in
vivo, gastrointestinal transit was measured at 22e23 h after IM.
About 30% of the orally administered phenol red labelled
content remained inside the stomach and 70% of it was trans-
ported down the intestine to the distal end of ileum with a peak
(SI9) in control healthy rats (ﬁgure 6A). The averaged calculated
geometric centre for the control animals was 6.6360.41 for 11
segments of the gastrointestinal tract (ﬁgure 6E). In contrast, IM
caused a signiﬁcant delay in gastrointestinal transit after a 1-h
transit period, and 70% of the orally administered content
remained in the stomach, whereas 30% of the transported
content was moved around the jejunum and proximal ileum.
The geometric centre was 2.6060.49 (n¼4, ﬁgure 6B, E). The
administration of MOS signiﬁcantly recovered the delayed
gastrointestinal transit and reduced the value of the geometric
centre after IM (ﬁgure 6C, E). Furthermore, MLA (0.087 mg/kg
s.c.) signiﬁcantly inhibited the ameliorative action of MOS on
the delayed gastrointestinal transit caused by IM (ﬁgure 6D, E)
in which 50% of the orally administered content remained in the
stomach, and 50% of the transported content was moved
around the jejunum and proximal ileum (geometric centre value:
3.4760.61, n¼4). MOS did not affect gastrointestinal transit of
control healthy rat (6.7360.92, n¼4), suggesting that MOS does
not induce gastrointestinal prokinetic action in the current
experimental condition.
ED1- and ED2-positive macrophages express a7nAChR whereas
neutrophils do not
We investigated which cells in the intestinal wall express
a7nAChR cells after IM using a-bungarotoxin (a-BTX) conju-
gated with ﬂuorescein isothiocyanate (FITC) (ﬁgures 7 and 8).
We rarely detected a-BTX-bound cells in the myenteric plexus
and serosal regions of control ileal tissues (myenteric plexus and
subserosal regions, 10.461.86 and 5.6661.72 cells/mm
2,
respectively; n¼4). In contrast, many a-BTX-positive cells were
detected in both regions of inﬂamed ileal tissues (myenteric
plexus and subserosal regions, 760.5640.67 and 750.49659.53
cells/mm
2;n ¼4 each). We double-stained specimens of the
inﬂamed muscle layer with ED1- and ED2-antibody or MPO and
FITC-labelled a-BTX. Over 50% of the population of round
ED2-positive activated resident macrophages bound to a-BTX
and the ratios of ED1-positive inﬁltrating macrophages that
bound to a-BTX were similar in both regions of the inﬂamed
muscle layer (ﬁgures 8). In contrast, MPO-positive neutrophils
did not react with a-BTX (ﬁgure 7).
Figure 5 Quantiﬁcation of antagonistic effects of hexamethonium and
MLA on MOS-induced anti-inﬂammatory activities determined as
leucocyte inﬁltration and intestinal motility dysfunction in POI model rats.
Numbers of ED1-positive monocyte-derived macrophages (A) and MPO-
stained neutrophils (B).
#, ** and jj, signiﬁcantly different from control,
IM (IM), and IM plus MOS (IM + MOS), respectively. Bars indicate
means 6 SEM from four independent experiments. Changes in intestinal
muscle contraction by CCh (C). MOS citrate (1 mg/kg, s.c.),
hexamethonium (1 mg/kg, i.p.) and MLA citrate (0.087 mg/kg, i.p.) were
administered as described in Materials and methods; **, signiﬁcantly
different from IM+MOS (n¼4 each). CCh, carbachol chloride; IM,
intestinal manipulation; MLA, methyl lycaconitine; MOS, mosapride
citrate; MPO, myeloperoxidase; POI, post-operative ileus.
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using anti-a7nAChR and anti-ED1 or anti-ED2 antibodies.
Many cells were double stained with anti-a7nAChR and anti-
ED1 or anti-ED2 antibodies in the inﬂamed myenteric plexus
region at 24 h after IM (ﬁgure 9A, B: ED2 and anti-a7nAChR,
136.61627.98 cells per mm
2; ED1 and anti-a7nAChR,
256.44648.21 cells per mm
2.n ¼4 each). We also performed
double staining using anti-a7nAChR antibody and a-BTX.
The results indicated that almost all anti-a7nAChR antibody-
positive and a-BTX-positive cells merged (ﬁgure 9C, n¼4).
DISCUSSION
Muscularis inﬂammation induces a motility disorder at the
prolonged phase of POI.
12 We demonstrated here that the
gastroprokinetic agent MOS ameliorates the motility dysfunc-
tion in the POI. Furthermore, we showed that MOS signiﬁcantly
suppressed macrophage and neutrophil inﬁltration into the
inﬂamed region, suggesting that an anti-inﬂammatory reaction is
involved. It is possible that the ameliorative action of MOS on
the motility dysfunction might be induced by gastrointestinal
prokinetic ability due to MOS remaining in the isolated ileal
tissue under assay conditions. However, this is unlikely because
rats rapidly eliminate MOS with a t½ of 1.9 h,
32 and we isolated
intestinal tissues at18 hafter theﬁnal administration ofMOS(at
the time of measuring contractile activity), when the MOS
concentration in the muscle tissue would be insufﬁcient to
induce a prokinetic reaction. We then questioned whether the
ameliorative actions of MOS both on motility dysfunction and
inﬂammation are mediated by selective action through the
5-HT4R, because MOS metabolites have antagonistic effects on
5-HT3 receptors.
33 The potent and selective 5-HT4R agonist
CJ-033466
34 35 ameliorated the motility dysfunction and the
inﬁltration of leucocytes induced by IM. In addition, the selective
5-HT4R antagonist GR113808
36 abolished the effects of MOS.
We thus concluded that 5-HT4R stimulation restores the motility
dysfunction in POI via an anti-inﬂammatory mechanism that is
independent of prokinetic ability.
Immune reactive cells such as dendritic cells also express
5-HT4R.
37 Activation of the 5-HT4R inhibits TNFa but increases
the production of IL-1b and IFNg. Thus, 5-HT4R agonists might
directly act on inﬂammatory cells such as macrophages and
neutrophils. Therefore, we next examined whether the effect of
5-HT4R agonists is mediated through direct actions on these
immune cells or through the neurogenic mechanisms. We found
that the non-speciﬁc autonomic ganglionic blocker HEX
completely suppressed the 5-HT4R stimulation-mediated anti-
inﬂammatory reaction, suggesting that 5-HT4R stimulation
in POI exerts neuronal anti-inﬂammatory actions. Unlike
the observation in human dendritic cells,
37 5-HT4R mRNA
expression was undetectable in rat peritoneal macrophages
(supplementary ﬁgure 1). Regarding the neurogenic mechanism
of anti-inﬂammatory actions induced by 5-HT4R agonists,
recent understanding of the control mechanisms of intestinal
inﬂammation exerted by autonomic nervous systems should
be considered. For instance, Tanila and Kauppila reported that
a selective a2-adrenergic antagonist reversed laparotomy-induced
Figure 6 Ameliorative action of
5-HT4R activation and negative effect of
MLA on gastrointestinal transit in POI
model rats. (AeD) Detailed procedures
are described in Materials and methods.
Gastrointestinal transit 1 h after food
intake was measured. Each bar
indicates means 6 SEM from four
independent experiments. (E) Values of
geometric centre of four groups
(control, IM + vehicle, IM + MOS, IM
+ MOS + MLA) were shown.
##,* *
and jj, signiﬁcantly different from
control, IM (IM), IM plus MOS (IM +
MOS), respectively. IM, intestinal
manipulation; MLA, methyl lycaconitine;
MOS, mosapride citrate; POI,
post-operative ileus.
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38 Kreiss et al.
39
demonstrated that macrophages inﬁltrating the muscularis after
IM express a2-adrenergic receptors. Furthermore, RAW264.7
macrophages are capable of synthesising catecholamines,
40
suggesting that released catecholamines can react with
a2-adrenergic receptors on macrophages in an autocrine and
a paracrine manner to complicate POI. As an alternative auto-
nomic regulation of inﬂammation, several investigators have
suggested that vagus nerve stimulation attenuates gastrointes-
tinal inﬂammations.
41e45 Wang et al recently found that nico-
tine inhibits the production of pro-inﬂammatory cytokines from
macrophages more efﬁciently than ACh.
42 On the other hand,
many type of immune cells such as lymphocytes, dendritic cells
and monocyte/macrophages are now recognised to express
a7nAChR.
31 The activation of a7nAChR triggers a spectrum of
anti-inﬂammatory signalling mechanisms that directly or indi-
rectly inhibit NF-kB activation and/or Jak/STAT3 pathway in
inﬂammatory cells.
31 We found here that the a7nAChR antag-
onist MLA almost completely suppressed the anti-inﬂammatory
action mediated by 5-HT4R stimulation. The amelioration of
intestinal dysmotility by 5-HT4R agonists was also abolished by
MLA. These results suggest that a7nAChR is involved in the
ameliorative action of 5-HT4R stimulation on POI.
The present study focused on the role of monocyte/macro-
phage lineage cells because evidence suggests that these cells
express abundant a7nAChR.
31 Our immunohistochemical study
of inﬂamed intestinal tissues showed that some ED1- and ED2-
positive macrophages, but not MPO-stained neutrophils, had
binding afﬁnity for a-BTX and were stained with anti-a7nAChR
antibody. Although the variety of nAChR subunits allows for
a diversity of combinations, the MLA-sensitive receptors with
high afﬁnity for a-BTX could be a7nAChR, because a-BTX or
MLA has binding afﬁnity for the a1, a7 and a9, or a6 and a7
isoforms of nAChR.
46 We further analysed the distribution of
a7nAChR in more detail in control and inﬂamed small intestine
musculature. We detected only a small population of a-BTX or
anti-a7nAChR antibody-positive leucocytes in the myenteric
plexus and subserosal regions of the normal rat small intestine.
Figure 7 Double staining with a-bungarotoxin and ED1- or ED2-
positive macrophages or myeloperoxidase (MPO)-stained neutrophils in
myenteric plexus region isolated from normal and a post-operative ileus
(POI) model rat ileum. Data are typical ﬁndings from four independent
experiments. Green signals, a-bungarotoxin-bound cells possibly
indicating a7nAChR expression; red signals, anti-ED1 or anti-ED2
antibody stained macrophages.
Figure 8 Summary of cell populations stained with a-bungarotoxin and
ED1- or ED2-positive macrophages in myenteric plexus and subserosal
region isolated from normal and POI model rat ileum. Each column
shows mean 6 SEM from four independent experiments. The
quantitative method is shown in the Materials and methods.
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ED2-positive activated resident macrophages with a round form
and ED1-positive monocyte-derived inﬁltrating macrophages
expressed a7nAChR in POI model rats. ED2-positive activated
resident macrophages are derived from self-multiplication at the
early stage of intestinal inﬂammation.
47 ED1-positive inﬁltrating
macrophages might also transform to ED2-positive resident
macrophages, which become stainable for both ED1 and
ED2.
47e49ThesereportsalsoindicatethepossibilitythatED1and
ED2 double positive macrophages may also express a7nAChR.
Although many reports indicate that a7nAChR is expressed in
macrophages and neutrophils, several others suggest otherwise.
Therefore, Van Der Zanden and colleagues posited that
a7nAChR expression on leucocytes is questionable.
50 We did not
detect a7nAChR mRNA expression in rat resident peritoneal
macrophages (supplementary ﬁgure 1). In contrast, a7nAChR
mRNA was detectable in peritoneal macrophages stimulated
with LPS (1 mg/ml) for 20 h, although not at very high levels.
Recent studies have also indicated that a7nAChR expression is
upregulated in macrophage-like U937 cells stimulated with
LPS
51 and in alveolar macrophages by acid-induced acute lung
injury.
52 Taken together, we support the idea that a7nAChR
expression is modulated by the maturation and transformation
of either resident or monocyte-derived intestinal muscularis
macrophages by inﬂammatory mediators.
Neutrophils apparently express nicotinic receptors, although
whether one of these receptor types is a7nAChR remains
unclear.
31 53 One recent study found that neutrophils in the
injured lung express a7nAChR.
52 However, neutrophils
expressing a7nAChR are unlikely in the inﬂamed intestine,
because a-BTX did not bind to inﬁltrated neutrophils stained
with MPO in the present study. On the other hand, Saeed et al
reported that microvascular endothelial cells express
a7nAChR.
54 They clariﬁed that vagus nerve stimulation and
cholinergic agonists signiﬁcantly block leucocyte migration
through a7nAChR in the carrageenan air pouch model.
However, we did not detect microvascular tubes that were both
a-BTX-positive and stained with anti-a7nAChR antibody in the
myenteric plexus region of the small intestine either before or
after inducing inﬂammation by IM.
We found in this study that 5-HT4R stimulation of myenteric
neurons ameliorates intestinal inﬂammation induced by IM,
which results in recovered motility function. The 5-HT4R might
mediate anti-inﬂammatory actions by stimulating cholinergic
neurons of the myenteric plexus to release ACh, which in turn
activates a7nAChR on muscularis resident macrophages and
monocyte-derived inﬁltrating macrophages to suppress inﬂam-
mation due to IM (ﬁgure 10). On the other hand, it has been
suggested that intestinal muscularis mast cells play a pivotal role
in the inﬂammation induced by IM
55; that is, mast cell activa-
tion induces leucocyte inﬁltration to accelerate muscularis
inﬂammation in POI. A recent report has shown that the
RBL2H3 rat mast cell line expresses a7, a9 and a10 isoforms of
nAChR.
56 The authors suggested that these three isoforms
functionally interact, indicating the possibility of a hybrid
nAChR. Therefore, the released ACh might also act on the
nAChRs of mast cells to inhibit leucocyte inﬁltration. Further
investigation is necessary to clarify this point.
In conclusion, although 5-HT4R agonists such as MOS are
clinically validated as therapies for gastrointestinal disorders
Figure 9 Double staining with anti-a7nAChR antibody and ED1- or
ED2-positive macrophages in the myenteric plexus region isolated from
normal and post-operative ileus (POI) model rat ileum. Data are typical
ﬁndings from ﬁve independent experiments. (A and B) Green signals,
anti-ED2 or anti-ED1 antibody-positive macrophages; red signals, anti-
a7nAChR antibody-positive cells. (C) Immunohistochemistry stained
with anti-a7nAChR antibody and a-bungarotoxin (BTX). Green signals,
FITC conjugated a-bungarotoxin-positive cells; red signals, anti-
a7nAChR antibody-positive cells.
Figure 10 Anti-inﬂammatory mechanisms of 5-HT4R stimulation in
post-operative ileus (POI). Stimulation of 5-HT4R in myenteric plexus
nerve results in release of acetyl choline (ACh), which in turn activates
a7nAChR on activated resident macrophages and inﬁltrating monocyte-
derived macrophages (but not on neutrophils), which prevents leucocyte
inﬁltration and subsequently inhibits inﬂammation and motility disorders.
ACh released from myenteric plexus nerve might also act on a7, a9 and
a10 isoforms of nAChRs of mast cells to prevent inﬂammation (see de
Jonge et al
55 and Mishra et al
56).
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Neurogastroenterologycharacterised by dysmotility, the present ﬁndings provide
new insights indicating that 5-HT4R agonists can also serve as
anti-inﬂammatory agents to treat diseases associated with
gastrointestinal motility.
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